Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neoepitope-specific monoclonal antibodies.
Blood dendritic cells carry the terminal complement complex (TCC) on their surface, as detected by three monoclonal antibodies (mAb). Two of these mAb were generated by immunizing mice with the terminal complement complex, whereas the third was generated by immunizing mice with blood dendritic cells. All three mAb are directed against neoepitopes on the C9 molecule, as assessed by binding and blocking experiments and studies with several forms of denatured C9 and C9-depleted serum. Only one of these mAb binds to soluble polymerized C9. All three mAb allow the quantification of human TCC in sensitive ELISA procedures and could be used as markers for the evaluation of the functions of non-lytic TCC on dendritic cells.
Würzner
R
R
Department of Immunology, Georg-August-University Göttingen, Germany.
Xu
H
H
Franzke
A
A
Schulze
M
M
Peters
J H
JH
Götze
O
O
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D002469:Cell Separation; D003186:Complement C9 / Q000276:immunology; D015938:Complement Membrane Attack Complex / Q000032:analysis*; D003429:Cross Reactions; D003713:Dendritic Cells / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000032:analysis; D005434:Flow Cytometry; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D011485:Protein Binding
D000911:Antibodies, Monoclonal; D003186:Complement C9; D015938:Complement Membrane Attack Complex; D000939:Epitopes